Intrathecal Dexmedetomidine to Decrease Postoperative Nausea and Vomiting and Shivering.

Can Subarachnoid Dexmedetomidine Decrease the Incidence of Postoperative Nausea and Vomiting and Shivering With Minimal Hemodynamic Instability in CS?

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05892705

Enrollment

Registered

2023-06-07

Start date

2021-06-01

Completion date

2023-01-15

Last updated

2023-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intrathecal Dexmedetomidine

Brief summary

Background: Highly selective α-2 agonist dexmedetomidine in increasingly used as an intrathecal adjuvant for caesarean section performed under subarachnoid block. Aim of the Study: The aim of the study is to determine whether low dose dexmedetomidine added to local anesthetic for spinal anesthesia will attenuate perioperative nausea and vomiting and shivering in lower segment caesarean section (LSCS) with minimal hemodynamic instability or not. Patients and Methods: Sixty parturients planned for elective CSs under spinal anesthesia were enrolled in this prospective controlled study and randomly divided into two equal groups. Spinal block was achieved with 10mg hyperbaric bupivacaine 0.5% plus 5µg dexmedetomidine (group D) (dexmedetomidine group) or 0.2 ml normal saline (group C) (control group). Hemodynamic parameters, incidence of nausea and vomiting and shivering were recorded. Keywords: Dexmedetomidine, Cesarean Section, Bupivacaine, Spinal Anesthesia, Shivering, PONV

Interventions

DRUGDexmedetomidine Injection [Precedex]

intrathecal injection of 5 mcg dexmedetomidine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 30 Years

Healthy volunteers

Yes

Inclusion criteria

* Medically free pregnant Female from 18 to 30 yrs old. * Undergoing elective LSCS. * Body mass index less than 40. * Consenting for sub arachnoid anesthesia. * Coagulation profile is within normal ranges.

Exclusion criteria

* Emergency LSCS. * Patient refusal enrollment in the study. * Allergy to the medications. * Coagulopathy or anticoagulation drugs. * Fetal or Maternal comorbidities.

Design outcomes

Primary

Measure	Time frame	Description
Effect of subarachnoid dexmedetomidine on hemodynamic parameters.	Two hours	Measure heart rate, blood pressure, temperature, oxygen saturation

Secondary

Measure	Time frame	Description
Effect of subarachnoid dexmedetomidine on incidence of postoperative nausea and vomiting (PONV) and shivering.	Six hours	Note occurrence of postoperative nausea or vomiting and note occurrence of shivering and measure the degree.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026